文献速递临床试验与 GCP基础与转化研究

细胞注射与皮质类固醇注射治疗膝骨关节炎疼痛:一项随机3期试验

Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.
PubMed 文献 · Nat Med · 2023-11-02

该研究为2/3期四臂平行多中心单盲随机对照试验,纳入480例Kellgren-Lawrence II-IV级膝骨关节炎患者,比较自体骨髓穿刺浓缩液、自体脂肪基质血管组分、异体人脐带组织来源间充质基质细胞注射与皮质类固醇注射(CSI)的疗效与安全性。主要终点为12个月时视觉模拟量表疼痛评分和膝关节损伤与骨关节炎结局评分疼痛评分较基线的变化;440例分析显示,注射后1年三种骨科生物制剂注射均未优于彼此或CSI对照组,四组磁共振成像骨关节炎评分较基线均无显著变化,研究期间未报告操作相关严重不良事件。

要点

  • 注射后1年,三种细胞注射均未优于皮质类固醇注射或彼此。
  • 四组磁共振成像骨关节炎评分较基线均无显著变化。
  • 研究期间未报告操作相关严重不良事件。

核心结论

  • 注射后1年,三种骨科生物制剂注射治疗膝骨关节炎均未优于皮质类固醇注射。

研究设计与样本

  • 2/3期四臂平行多中心单盲随机对照试验,纳入480例Kellgren-Lawrence II-IV级膝骨关节炎患者。
  • 参与者按3:1分配至三种细胞注射组各120例与相应CSI组各40例。
  • 主要终点为12个月时视觉模拟量表疼痛评分和膝关节损伤与骨关节炎结局评分疼痛评分较基线的变化。

主要发现

  • 440例患者的主要终点分析显示,注射后1年三种骨科生物制剂注射均未优于彼此或CSI对照组。
  • 四组磁共振成像骨关节炎评分较基线均无显著变化。
  • 研究期间未报告操作相关严重不良事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Various types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections. Here we aimed to identify the safety and efficacy of cell injections from autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticosteroid injection (CSI). The study was a phase 2/3, four-arm parallel, multicenter, single-blind, randomized, controlled clinical trial with 480 patients with a diagnosis of knee osteoarthritis (Kellgren-Lawrence II-IV). Participants were randomized to the three different arms with a 3:1 distribution. Arm 1: autologous bone marrow aspirate concentrate (n = 120), CSI (n = 40); arm 2: umbilical cord tissue-derived mesenchymal stromal cells (n = 120), CSI (n = 40); arm 3: stromal vascular fraction (n = 120), CSI (n = 40). The co-primary endpoints were the visual analog scale pain score and Knee injury and Osteoarthritis Outcome Score pain score at 12 months versus baseline. Analyses of our primary endpoints, with 440 patients, revealed that at 1 year post injection, none of the three orthobiologic injections was superior to another, or to the CSI control. In addition, none of the four groups showed a significant change in magnetic resonance imaging osteoarthritis score compared to baseline. No procedure-related serious adverse events were reported during the study period. In summary, this study shows that at 1 year post injection, there was no superior orthobiologic as compared to CSI for knee osteoarthritis. ClinicalTrials.gov Identifier: NCT03818737.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med. 2023. PMID: 37919438. doi:10.1038/s41591-023-02632-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。